Myomo, Inc. (MYO)
| Market Cap | 39.80M -67.1% |
| Revenue (ttm) | 41.21M +6.7% |
| Net Income | -15.12M |
| EPS | -0.39 |
| Shares Out | 38.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 627,729 |
| Open | 1.070 |
| Previous Close | 1.040 |
| Day's Range | 1.010 - 1.070 |
| 52-Week Range | 0.605 - 3.220 |
| Beta | 1.39 |
| Analysts | Strong Buy |
| Price Target | 4.32 (+319.42%) |
| Earnings Date | May 7, 2026 |
About MYO
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the bra... [Read more]
Financial Performance
In 2025, Myomo's revenue was $40.93 million, an increase of 25.73% compared to the previous year's $32.55 million. Losses were -$15.57 million, 151.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for MYO stock is "Strong Buy." The 12-month stock price target is $4.32, which is an increase of 319.42% from the latest price.
News
Myomo Transcript: Sidoti Micro-Cap Virtual Conference
The company leverages a first-mover advantage in wearable robotics for upper extremity paralysis, expanding market access and recurring revenue streams through payer contracts and referral programs. Product innovation, clinical validation, and operational efficiency drive growth, with a focus on reaching cash flow break-even as recurring revenues rise.
Myomo Transcript: A.G.P.'s Annual Virtual Healthcare Conference
A proprietary orthotic device for stroke survivors is driving growth through expanded Medicare coverage, recurring revenue channels, and partnerships with national providers. Revenue guidance for 2024 is $43–$46 million, with a reduced break-even point and targeted lower cash burn.
Myomo Slides: Investor presentation
Myomo has posted slides in relation to its latest quarterly earnings report, which was published on May 20, 2026.
Myomo Announces Participation in Upcoming Investor Conferences
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Proxy statement: Proxy filing
Myomo filed a proxy statement on May 14, 2026, providing details for shareholder voting and corporate governance matters.
Myomo Proxy statement: Proxy filing
Myomo filed a proxy statement on May 14, 2026, providing details for shareholder voting and corporate governance matters.
Myomo Slides: Corporate presentation
Myomo has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Myomo Appoints Joseph M. Manko to its Board of Directors
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo reports Q1 EPS (7c), consensus (12c)
Reports Q1 revenue $10.1M, consensus $9.2M. “Earlier this year we established four success pillars for 2026, including growing revenue from recurring patient sources, increasing market access, demonst...
Myomo sees Q2 revenue $10.3M-$10.8M, consensus $10.5M
“With a strong backlog entering the second quarter, we expect to grow revenue sequentially with modestly higher operating expenses from increased advertising spend as changes made in our marketing pro...
Myomo Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose 3% to $10.1M, with gross margin up to 68.2% and net loss narrowing to $3M. Recurring patient sources now drive 49% of revenue, and international growth remains strong. Full-year guidance is reiterated at $43–$46M.
Myomo Earnings release: Q1 2026
Myomo released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Myomo Quarterly report: Q1 2026
Myomo has published its Q1 2026 quarterly earnings report on May 7, 2026.
Myomo Shareholder letter: Q1 2026
Myomo has published a letter to shareholders covering Q1 2026, which was released on May 7, 2026.
Myomo Reports First Quarter 2026 Financial and Operating Results
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo announce availability of MyoPro at Ottobock Care Clinics
Myomo (MYO) announces expanded access to the MyoPro device through Ottobock Care clinics nationwide. Ottobock Care will offer the MyoPro through its clinics across the country, helping individuals wit...
Myomo Announces Availability of MyoPro at Ottobock Care Clinics in the U.S.
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company and manufacturer of the MyoPro® powered arm brace, announces expanded access to the MyoPro dev...
Myomo Proxy statement: Proxy filing
Myomo filed a proxy statement on May 4, 2026, providing details for shareholder voting and corporate governance matters.
Myomo to Report First Quarter 2026 Financial Results on May 7
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo launches Myomo Mobile App
Myomo (MYO) announces the launch of the Myomo Mobile App, a new digital tool designed to support clinicians and patients throughout the MyoPro experience. “For clinicians, the Myomo Mobile App…
Myomo Introduces Myomo Mobile App to Enhance Clinical Workflow and Patient Engagement
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company that offers increased functionality for people with neurological disorders and upper-limb para...
Myomo Appoints William J Febbo to its Board of Directors
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Slides: Investor presentation
Myomo has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
Myomo price target lowered to $3 from $4 at Alliance Global
Alliance Global lowered the firm’s price target on Myomo (MYO) to $3 from $4 and keeps a Buy rating on the shares following the Q4 report. The firm cites its…
Myomo Earnings Call Transcript: Q4 2025
Revenue grew 26% to $40.9M in 2025, with record Q4 orders and strong O&P and international growth. Recurring sources now make up 42% of Q4 revenue, and 2026 guidance targets $43–$46M revenue, higher gross margin, and halved cash burn.